Liquorice Root
Liquiritiae radix
Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch.
HOS-215945hmpc:liquiritiae-radix
Botanische Abbildung · Noch nicht verfügbar
Für die botanische Originalangabe wurde noch kein eindeutig zugeordnetes Bild gefunden.
- Themengebiete laut EMA
- Cough and cold;Gastrointestinal disorders
- Ergebnis der Bewertung laut EMA
- European Union herbal monograph
- Kombination laut EMA
- Nein
Pflanzen–Arzneimittel-Beziehungen 2 belegte Zuordnungen
Warnungen, berichtete Effekte und verneinte Studienbefunde werden getrennt ausgewiesen und mit eindeutig bezeichneten Wirkstoffen verknüpft. Jede Aussage gilt im Zubereitungs- und Anwendungskontext der Quelle. Ein klinischer Schweregrad wird daraus nicht abgeleitet.
midazolam
Berichteter EffektTraditionelle Anwendung · Quellenspalte · Keine wirkstoffbezogene Einschränkung abgeleitet · Schweregrad: nicht angegeben
Die Quelle beschreibt einen möglichen oder beobachteten Effekt; auch ein Verdachtsfall ist damit möglich. Allgemeine Warnungen und weitere Bedingungen bleiben im Originalzitat erhalten. Daraus wurde hier keine zusätzliche Einschränkung für den einzelnen Wirkstoff abgeleitet.
HOS-215945HOS-086167RxNorm 6960
Liquorice root preparations might affect the activity of CYP3A4. Clinical studies have shown that the oral intake of 300 mg/day of glycyrrhizin for 14 days can modestly decrease the systemic exposure to drugs metabolised by CYP 3A4 enzymes such as midazolam and omeprazole. Caution is advised in case of concomitant use of all drug substances the metabolism of which is influenced by CYP3A4.
Zubereitungskontext & Beleg
Wortlaut der zugeordneten Aussage:
Clinical studies have shown that the oral intake of 300 mg/day of glycyrrhizin for 14 days can modestly decrease the systemic exposure to drugs metabolised by CYP 3A4 enzymes such as midazolam and omeprazole.
1. Name of the medicinal product To be specified for the individual finished product. 2. Qualitative and quantitative composition2, 3 Well-established use Traditional use With regard to the registration application of Article 16d(1) of Directive 2001/83/EC Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix (liquorice root) i) Herbal substance Not applicable. ii) Herbal preparations a) Comminuted herbal substance b) Soft extract (DER 1:0.4-0.5), extraction solvent water c) Soft extract (DER 3:1), extraction solvent water 3. Pharmaceutical form Well-established use Traditional use Comminuted herbal substance as herbal tea for oral use. Herbal preparations in liquid dosage forms for oral use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term. 2 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. 3 The material complies with the Ph. Eur. monograph (ref.: 01/2012:0277). European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix EMA/HMPC/108399/2024 Page 3/8 4. Clinical particulars 4.1. Therapeutic indications Well-established use Traditional use Indication 1) Traditional herbal medicinal product for the relief of digestive symptoms including burning sensation and dyspepsia. Indication 2) Traditional herbal medicinal product used as an expectorant in cough associated with cold. The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. 4.2. Posology and method of administration4 Well-established use Traditional use Posology Indication 1) Adults and elderly a) Comminuted herbal substance Herbal tea: 1.5 - 2 g of comminuted herbal substance in 150 ml of boiling water as an herbal infusion or decoction, 2 to 4 times daily. Take one cup after meals. Daily dose: 3 – 8 g. b) Soft extract (DER 1:0.4-0.5) Single dose: 32 mg, 2-3 times daily. Daily dose: 64 – 96 mg (max 160 mg daily). Indication 2) Adults and elderly a) Comminuted herbal substance Herbal tea: 1.5 g – 4.5 g of comminuted herbal substance in 150 ml of boiling water as an herbal infusion or decoction, 2-3 times daily. 4 For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC ‘Glossary on herbal teas’ (EMA/HMPC/5829/2010 Rev.1). European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix EMA/HMPC/108399/2024 Page 4/8 Well-established use Traditional use Daily dose: 3 – 13.5 g. c) Soft extract (DER 3:1) Single dose: 1.2-1.5 g, 3-4 times daily. Daily dose: 3.6 – 6 g. The use in children and adolescents under 18 years of age is not recommended (see section 4.4 ‘Special warnings and precautions for use’). Duration of use Indication 1) Not to be used for more than 4 weeks. If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Indication 2) If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Method of administration Oral use. 4.5. Interactions with other medicinal products and other forms of interaction Well-established use Traditional use Liquorice root may counteract antihypertensive action of prescribed medications. Not to be used concomitantly with diuretics, cardiac glycosides, corticosteroids, stimulant laxatives or other medications which may aggravate electrolyte imbalance (see section with 4.4). Liquorice root preparations might affect the activity of CYP3A4. Clinical studies have shown that the oral intake of 300 mg/day of glycyrrhizin for 14 days can modestly decrease the systemic exposure to drugs metabolised by CYP 3A4 enzymes such as midazolam and omeprazole. Caution is advised in case of concomitant use of all drug substances the metabolism of which is influenced by CYP3A4. European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix EMA/HMPC/108399/2024 Page 6/8PDF SHA-256:
6268fc46479f2a55f474a2533811e5dddd27548334dba8b774bf252267137989Die Zuordnung verbindet dieses HMPC-Quellenprofil mit dem genannten Wirkstoff. Sie ist keine Aussage über jedes Präparat aus dieser Pflanzenart.
omeprazole
Berichteter EffektTraditionelle Anwendung · Quellenspalte · Keine wirkstoffbezogene Einschränkung abgeleitet · Schweregrad: nicht angegeben
Die Quelle beschreibt einen möglichen oder beobachteten Effekt; auch ein Verdachtsfall ist damit möglich. Allgemeine Warnungen und weitere Bedingungen bleiben im Originalzitat erhalten. Daraus wurde hier keine zusätzliche Einschränkung für den einzelnen Wirkstoff abgeleitet.
HOS-215945HOS-085912RxNorm 7646
Liquorice root preparations might affect the activity of CYP3A4. Clinical studies have shown that the oral intake of 300 mg/day of glycyrrhizin for 14 days can modestly decrease the systemic exposure to drugs metabolised by CYP 3A4 enzymes such as midazolam and omeprazole. Caution is advised in case of concomitant use of all drug substances the metabolism of which is influenced by CYP3A4.
Zubereitungskontext & Beleg
Wortlaut der zugeordneten Aussage:
Clinical studies have shown that the oral intake of 300 mg/day of glycyrrhizin for 14 days can modestly decrease the systemic exposure to drugs metabolised by CYP 3A4 enzymes such as midazolam and omeprazole.
1. Name of the medicinal product To be specified for the individual finished product. 2. Qualitative and quantitative composition2, 3 Well-established use Traditional use With regard to the registration application of Article 16d(1) of Directive 2001/83/EC Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix (liquorice root) i) Herbal substance Not applicable. ii) Herbal preparations a) Comminuted herbal substance b) Soft extract (DER 1:0.4-0.5), extraction solvent water c) Soft extract (DER 3:1), extraction solvent water 3. Pharmaceutical form Well-established use Traditional use Comminuted herbal substance as herbal tea for oral use. Herbal preparations in liquid dosage forms for oral use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term. 2 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. 3 The material complies with the Ph. Eur. monograph (ref.: 01/2012:0277). European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix EMA/HMPC/108399/2024 Page 3/8 4. Clinical particulars 4.1. Therapeutic indications Well-established use Traditional use Indication 1) Traditional herbal medicinal product for the relief of digestive symptoms including burning sensation and dyspepsia. Indication 2) Traditional herbal medicinal product used as an expectorant in cough associated with cold. The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. 4.2. Posology and method of administration4 Well-established use Traditional use Posology Indication 1) Adults and elderly a) Comminuted herbal substance Herbal tea: 1.5 - 2 g of comminuted herbal substance in 150 ml of boiling water as an herbal infusion or decoction, 2 to 4 times daily. Take one cup after meals. Daily dose: 3 – 8 g. b) Soft extract (DER 1:0.4-0.5) Single dose: 32 mg, 2-3 times daily. Daily dose: 64 – 96 mg (max 160 mg daily). Indication 2) Adults and elderly a) Comminuted herbal substance Herbal tea: 1.5 g – 4.5 g of comminuted herbal substance in 150 ml of boiling water as an herbal infusion or decoction, 2-3 times daily. 4 For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC ‘Glossary on herbal teas’ (EMA/HMPC/5829/2010 Rev.1). European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix EMA/HMPC/108399/2024 Page 4/8 Well-established use Traditional use Daily dose: 3 – 13.5 g. c) Soft extract (DER 3:1) Single dose: 1.2-1.5 g, 3-4 times daily. Daily dose: 3.6 – 6 g. The use in children and adolescents under 18 years of age is not recommended (see section 4.4 ‘Special warnings and precautions for use’). Duration of use Indication 1) Not to be used for more than 4 weeks. If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Indication 2) If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Method of administration Oral use. 4.5. Interactions with other medicinal products and other forms of interaction Well-established use Traditional use Liquorice root may counteract antihypertensive action of prescribed medications. Not to be used concomitantly with diuretics, cardiac glycosides, corticosteroids, stimulant laxatives or other medications which may aggravate electrolyte imbalance (see section with 4.4). Liquorice root preparations might affect the activity of CYP3A4. Clinical studies have shown that the oral intake of 300 mg/day of glycyrrhizin for 14 days can modestly decrease the systemic exposure to drugs metabolised by CYP 3A4 enzymes such as midazolam and omeprazole. Caution is advised in case of concomitant use of all drug substances the metabolism of which is influenced by CYP3A4. European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix EMA/HMPC/108399/2024 Page 6/8PDF SHA-256:
6268fc46479f2a55f474a2533811e5dddd27548334dba8b774bf252267137989Die Zuordnung verbindet dieses HMPC-Quellenprofil mit dem genannten Wirkstoff. Sie ist keine Aussage über jedes Präparat aus dieser Pflanzenart.
Keine oder wenige Zuordnungen bedeuten nicht, dass keine Wechselwirkungen bestehen. Nicht eindeutig zuordenbare Aussagen bleiben im Originalabschnitt nachlesbar; verneinte Befunde gelten nur für die beschriebenen Bedingungen.
Sicherheit aus der Monographie Originalabschnitte
Englische Originalabschnitte mit unveränderten Spalten für etablierte und traditionelle Anwendung. Aussagen gelten für die im Dokument genannten Zubereitungen und Anwendungsarten. Aus ihnen werden hier keine Interaktionspaare oder Schweregrade abgeleitet.
Final European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix - Revision 1 ↗
PDF abgerufen: 25.10.2026 · 8 Seiten · automatisch ausgelesen
Zubereitungs- und Anwendungskontext · Originaltext
Originalkontext vor Abschnitt 4.3, einschließlich der Angaben zu Zubereitungen und Anwendung. Buchstaben und Nummern der Zubereitungen werden in den Sicherheitsabschnitten wieder aufgegriffen.
1. Name of the medicinal product
To be specified for the individual finished product.
2. Qualitative and quantitative composition2, 3
Well-established use Traditional use
With regard to the registration application of
Article 16d(1) of Directive 2001/83/EC
Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.;
Glycyrrhiza uralensis Fisch., radix (liquorice root)
i) Herbal substance
Not applicable.
ii) Herbal preparations
a) Comminuted herbal substance
b) Soft extract (DER 1:0.4-0.5), extraction
solvent water
c) Soft extract (DER 3:1), extraction solvent
water
3. Pharmaceutical form
Well-established use Traditional use
Comminuted herbal substance as herbal tea for
oral use.
Herbal preparations in liquid dosage forms for
oral use.
The pharmaceutical form should be described by
the European Pharmacopoeia full standard term.
2 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal
quality guidance.
3 The material complies with the Ph. Eur. monograph (ref.: 01/2012:0277).
European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix
EMA/HMPC/108399/2024 Page 3/8
4. Clinical particulars
4.1. Therapeutic indications
Well-established use Traditional use
Indication 1)
Traditional herbal medicinal product for the relief
of digestive symptoms including burning
sensation and dyspepsia.
Indication 2)
Traditional herbal medicinal product used as an
expectorant in cough associated with cold.
The product is a traditional herbal medicinal
product for use in specified indications
exclusively based upon long-standing use.
4.2. Posology and method of administration4
Well-established use Traditional use
Posology
Indication 1)
Adults and elderly
a) Comminuted herbal substance
Herbal tea: 1.5 - 2 g of comminuted herbal
substance in 150 ml of boiling water as an herbal
infusion or decoction, 2 to 4 times daily.
Take one cup after meals.
Daily dose: 3 – 8 g.
b) Soft extract (DER 1:0.4-0.5)
Single dose: 32 mg, 2-3 times daily.
Daily dose: 64 – 96 mg (max 160 mg daily).
Indication 2)
Adults and elderly
a) Comminuted herbal substance
Herbal tea: 1.5 g – 4.5 g of comminuted herbal
substance in 150 ml of boiling water as an herbal
infusion or decoction, 2-3 times daily.
4
For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate
preparation, please refer to the HMPC ‘Glossary on herbal teas’ (EMA/HMPC/5829/2010 Rev.1).
European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix
EMA/HMPC/108399/2024 Page 4/8
Well-established use Traditional use
Daily dose: 3 – 13.5 g.
c) Soft extract (DER 3:1)
Single dose: 1.2-1.5 g, 3-4 times daily.
Daily dose: 3.6 – 6 g.
The use in children and adolescents under 18
years of age is not recommended (see section
4.4 ‘Special warnings and precautions for use’).
Duration of use
Indication 1)
Not to be used for more than 4 weeks.
If the symptoms persist longer than 2 weeks
during the use of the medicinal product, a doctor
or a qualified health care practitioner should be
consulted.
Indication 2)
If the symptoms persist longer than 1 week
during the use of the medicinal product, a doctor
or a qualified health care practitioner should be
consulted.
Method of administration
Oral use.Kontext im Original-PDF öffnen ↗4.3 · Gegenanzeigen
Contraindications
4.3. Contraindications
Well-established use Traditional use
Hypersensitivity to the active substance(s)Original-PDF · Seite 5 ↗4.4 · Warnhinweise und Vorsichtsmaßnahmen
Special warnings and precautions for use
4.4. Special warnings and precautions for use
Well-established use Traditional use
Indications 1) and 2)
The use in children and adolescents under 18
years of age has not been established due to lack
of adequate data.
If the symptoms worsen during the use of the
medicinal product, a doctor or a qualified health
care practitioner should be consulted.
Patients taking liquorice medication should not
European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix
EMA/HMPC/108399/2024 Page 5/8
Well-established use Traditional use
take other liquorice containing products as
serious adverse events may occur such as water
retention, hypokalaemia, hypertension, cardiac
rhythm disorders.
Liquorice medication is not recommended in
patients affected by hypertension, kidney
diseases, liver or cardiovascular disorders or
hypokalaemia, as they are more sensitive to the
adverse effects of liquorice.
Concomitant use with diuretics, cardiac
glycosides, corticosteroids, stimulant laxatives or
other medications, which may aggravate
electrolyte imbalance, is not recommended (see
section 4.5).
Caution is advised when liquorice is taken
concomitantly with drugs known to be substrate
of CYP3A4 (see section 4.5).
Indication 2)
If dyspnoea, fever or purulent sputum occurs, a
doctor or a qualified health care practitioner
should be consulted.Original-PDF · Seite 5–6 ↗4.5 · Wechselwirkungen
Interactions with other medicinal products and other forms of interaction
4.5. Interactions with other medicinal products and other forms of
interaction
Well-established use Traditional use
Liquorice root may counteract antihypertensive
action of prescribed medications.
Not to be used concomitantly with diuretics,
cardiac glycosides, corticosteroids, stimulant
laxatives or other medications which may
aggravate electrolyte imbalance (see section with
4.4).
Liquorice root preparations might affect the
activity of CYP3A4. Clinical studies have shown
that the oral intake of 300 mg/day of glycyrrhizin
for 14 days can modestly decrease the systemic
exposure to drugs metabolised by CYP 3A4
enzymes such as midazolam and omeprazole.
Caution is advised in case of concomitant use of
all drug substances the metabolism of which is
influenced by CYP3A4.
European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix
EMA/HMPC/108399/2024 Page 6/8Original-PDF · Seite 6 ↗4.8 · Nebenwirkungen
Undesirable effects
4.8. Undesirable effects
Well-established use Traditional use
If adverse reactions occur, a doctor or a qualified
health care practitioner should be consulted.Original-PDF · Seite 7 ↗Dokumentfassung nachweisen
SHA-256: 6268fc46479f2a55f474a2533811e5dddd27548334dba8b774bf252267137989
Der Hash kennzeichnet die abgerufene Datei. Die Dokumentfassung und der Bearbeitungsstatus des Pflanzenprofils sind getrennte Angaben.
Importstand: 26.10.2026 · Aktuelles EMA-Quellenprofil ↗
Dokumente beim Herausgeber · 17
Originaltitel bleiben erhalten. Entwürfe, ältere Fassungen und ergänzende Berichte können nebeneinander vorliegen; der Profilstatus bestimmt nicht die Gültigkeit jedes Dokuments.
- Call for scientific data for the periodic review of the monograph on Liquiritiae radix - Revision 1
- Call for submission of scientific data relating to the assessment of Liquiritiae radix Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix (liquorice root) - First version
- Superseded overview of comments received on Community herbal monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version
- Draft Community herbal monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version
- Draft European Union herbal monograph on Glycyrrhiza glabra L.; Gycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix – Revision 1
- Final European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix - Revision 1
- Superseded Community herbal monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version
- Final opinion of the HMPC on a European Union herbal monograph on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix - Revision 1
- Opinion of the HMPC on a Community herbal monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version
- Draft list of references supporting the assessment of Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version
- Draft list of references supporting the assessment of Glycyrrhiza glabra L.; Gycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix - Revision 1
- Final list of references supporting the assessment of Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix - Revision 1
- Superseded list of references supporting the assessment of Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version
- Draft assessment report on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version
- Draft assessment report on on Glycyrrhiza glabra L.; Gycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix - Revision 1
- Superseded assessment report on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix - First version
- Final assessment report on Glycyrrhiza glabra L.; Glycyrrhiza inflata Bat.; Glycyrrhiza uralensis Fisch., radix - Revision 1
Dokumentenlinks geprüft: 25.10.2026
Quellenstand & Originalangaben
- Originalstatus
- F: Assessment finalised
- Zuletzt geändert laut EMA
- 20/07/2026
- Erstveröffentlichung laut EMA
- 31/12/2009
- Erfolgreicher Quellenabruf
- 26.10.2026